Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 18/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.65 |
| ▸ | SLC2A4 | P14672 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17718873 | 0.91 | SLC2A1 (1.00) | SLC2A1SMN1; SMN2SLC2A3SLC2A4 | |
| SCHEMBL17718852 | 0.88 | SLC2A1 (1.00) | SLC2A1SMN1; SMN2SLC2A3SLC2A4 | |
| SCHEMBL17718848 | 0.88 | SLC2A1 (0.89) | SLC2A1SMN1; SMN2SLC2A3SLC2A4 | |
| SCHEMBL16246716 | 0.86 | SLC2A1 (1.00) | SLC2A1SLC2A3SLC2A4 | |
| SCHEMBL17718919 | 0.86 | SLC2A1 (1.00) | SLC2A1SMN1; SMN2SLC2A3SLC2A4 | |
| SCHEMBL17718907 | 0.84 | SLC2A1 (1.00) | SLC2A1SLC2A3SLC2A4 | |
| SCHEMBL17719146 | 0.84 | SLC2A1 (0.85) | SLC2A1SMN1; SMN2SLC2A3SLC2A4 | |
| SCHEMBL17718876 | 0.83 | SLC2A1 (0.83) | SLC2A1SMN1; SMN2SLC2A3SLC2A4 | |
| SCHEMBL17718875 | 0.83 | SLC2A1 (1.00) | SLC2A1SMN1; SMN2 | |
| SCHEMBL17718904 | 0.82 | SLC2A1 (1.00) | SLC2A1SMN1; SMN2SLC2A3SLC2A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160120863-A1 | SLC2A TRANSPORTER INHIBITORS | IOMET PHARMA LTD. (GB) | 2016-05-05 | — | — | US | disclosed |
| US-20160120863-A1 | SLC2A TRANSPORTER INHIBITORS | IOMET PHARMA LTD. (GB) | 2016-05-05 | — | — | US | disclosed |
| US-20160120863-A1 | SLC2A TRANSPORTER INHIBITORS | IOMET PHARMA LTD. (GB) | 2016-05-05 | — | — | US | disclosed |
| EP-3004088-A1 | SLC2A TRANSPORTER INHIBITORS | Iomet Pharma Ltd. (GB) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014187922-A1 | SLC2A TRANSPORTER INHIBITORS | IOMET PHARMA LTD. (GB) | 2014-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160120863-A1 | SLC2A TRANSPORTER INHIBITORS | SLCO1A2, SLCO2B1, SLCO2A1 | SLC2A1 6/4885SMN1; SMN2 3724/4885SLC2A3 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.